Navigation Links
Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:4/13/2009

rapy should be discontinued. Patients should be advised of and avoid exposure to potential risk factors for infection as appropriate. For patients who have resided in or traveled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of SIMPONI treatment should be carefully considered before initiation of SIMPONI therapy. Patients must be evaluated for the risk of tuberculosis, including latent tuberculosis, prior to initiation of SIMPONI. Treatment of latent tuberculosis infection should be initiated prior to therapy with SIMPONI. Antituberculosis therapy prior to initiating SIMPONI should also be considered in patients who have several or highly significant risk factors for tuberculosis infection and have a negative test for latent tuberculosis. Patients receiving SIMPONI should be monitored closely for signs and symptoms of active tuberculosis during and after treatment, including patients who tested negative for latent tuberculosis infections. The use of TNF blocking agents has been associated with reactivation of hepatitis B virus in patients who are chronic carriers of the virus. Chronic carriers of hepatitis B should be appropriately evaluated and monitored prior to the initiation of, during treatment with, and for several months following discontinuation of SIMPONI.

Lymphomas have been observed in patients treated with TNF blocking agents, including SIMPONI. The incidence of non-lymphoma malignancies was similar to controls, and lymphoma is seen more often than in the general population. The potential role of TNF-blocking therapy in the development of malignancies is not known. Caution should be exercised when considering TNF-blocking therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy.

Worsening congestive heart failure (CHF) and new onset CH
'/>"/>

SOURCE Centocor Ortho Biotech Inc.; Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
2. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
3. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
4. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
5. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
6. Midwest Research Institute Expands in Kansas to Support Regional Economic Development in Animal Health, Biosecurity, and Bioenergy Sectors
7. Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress
8. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
9. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
10. MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets
11. Hoosiers Work for Health Highlights Impact of Medical Research and Innovation on Indiana Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Global Specimen Solutions, Inc. ( ... specimen management and informatics, announced today that Series ... Inc. is excited to catapult our growing momentum ... further enhance our proprietary informatics tools and infrastructure ... GSS has proved rapid market uptake of our ...
(Date:3/6/2015)... 06, 2015 Transparency Market Research has published ... Crops - Global Industry Analysis, Size, Share, Growth, Trends and ... isoxaflutole market was valued at US$ 116.3 Mn in 2013 ... expanding at a CAGR of 5.1% from 2014 to 2020. ... at 2,569.5 kilo tons in 2013. , Isoxaflutole is widely ...
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... 2015   HX360 today announced that sixteen ... HX360 Innovation Challenge competition. These companies, selected from ... chosen as one of four finalists to present their ... executives and venture capitalists during the Innovation Challenge event. ... at the 2015 HIMSS Annual Conference & Exhibition, McCormick ...
Breaking Biology Technology:Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 2Isoxaflutole Market is Expected to Reach US$ 163.0 Mn by 2020 : Transparency Market Research 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... NEW YORK, June 18 In designing and conducting ... while preventing program "drift," according to Matthew Lehman, chief ... remarks at a recent seminar for biotechnology companies. ... for Success: Balancing FDA Expectations and Operational Reality," at ...
... Germany, June 18 2009 is the year of the ... cytometer - the ICP 11. , ... State Vineyard Castle Wackerbarth near Dresden. For the festive,ceremony, CEO ... society. , In 1968, the fluorescence ...
... event and prepare for it, according to new research ... that appeared today in Nature , Prof. Yitzhak ... Orna Dahan of the Institute,s Molecular Genetics Department, together ... Aviv University, examined microorganisms living in environments that change ...
Cached Biology Technology:Matthew Lehman of SPRI Clinical Trials Speaks On Designing Trials For Success At The Trout Group Investor Relations Seminar 2A Worldwide Milestone in Cell Analysis - 40 Years of Flow Cytometry 2Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... 2015 Research and Markets ( ... "Global Biometrics Market (2014-2020): Market Forecast By ... report to their offering. , ... is anticipated to overtake North ... government spending towards IT security, government biometric based ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... -- A new study by Georgetown University Medical Center researchers ... to stop cancer cell growth. The findings, published online ... which is mutated in a majority of families who have ... I. Yarden, PhD, assistant professor in the Department of Human ...
... A new model of the how the protein coat ... access journal BMC Biophysics , shows that ... capsid production (hierarchical assembly) can be more efficient than ... capsid enveloping a virus is essential for protection and ...
... genomic data into meaningful information about the cell is ... human biology and medicine. Researchers at the University of ... proposed a new method that creates a computational model ... protein interactions, discovering how genes and proteins connect to ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Do-it-yourself viruses: How viruses self assemble 2Toward a new model of the cell 2Toward a new model of the cell 3
... by a modification of the procedure ... Bioeng., 11 , 1055 ... yield an A 260 of ... (1 cm light path). Physical Form: ...
... White solid.. PACKAGED UNDER INERT GAS. ... reaction is "driven" to completion. A protective agent ... found in many other preparations. Blocks the lethal ... by titration. Contaminants: Heavy metals: ≤1 ...
... Basically, most ``special`` dye stains ... a few other non-routine) stains are ... of a paraffin block, staining, coverslipping ... Stain (for senile plaques) ,Bodian`s Stain ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
Biology Products: